IEZZI, LAURA
 Distribuzione geografica
Continente #
NA - Nord America 1.001
EU - Europa 626
AS - Asia 368
SA - Sud America 6
AF - Africa 1
Totale 2.002
Nazione #
US - Stati Uniti d'America 1.001
CN - Cina 156
IE - Irlanda 127
IT - Italia 105
SE - Svezia 103
SG - Singapore 101
UA - Ucraina 72
FR - Francia 70
TR - Turchia 67
DE - Germania 61
GB - Regno Unito 33
IN - India 20
VN - Vietnam 20
RU - Federazione Russa 13
CZ - Repubblica Ceca 10
FI - Finlandia 10
AT - Austria 7
RO - Romania 5
BE - Belgio 4
BR - Brasile 2
HK - Hong Kong 2
PY - Paraguay 2
BG - Bulgaria 1
BO - Bolivia 1
CL - Cile 1
DK - Danimarca 1
JP - Giappone 1
LT - Lituania 1
MA - Marocco 1
NL - Olanda 1
PL - Polonia 1
PT - Portogallo 1
UZ - Uzbekistan 1
Totale 2.002
Città #
Chandler 237
Jacksonville 127
Dublin 126
Singapore 92
Dearborn 90
Ashburn 56
Houston 55
Princeton 52
Izmir 40
Nanjing 39
Wilmington 28
Altamura 26
Chieti 26
Munich 24
Beijing 23
Ann Arbor 21
Boardman 20
Dong Ket 20
Southend 16
Los Angeles 14
Cambridge 13
Kunming 13
Santa Clara 11
Nanchang 10
Washington 10
Brno 9
New York 9
Shenyang 9
Jiaxing 7
Norwalk 7
Vienna 7
Tianjin 6
Hebei 5
Helsinki 5
Pescara 5
Brussels 4
Hefei 4
London 4
Woodbridge 4
Zhengzhou 4
Chicago 3
Falls Church 3
Hangzhou 3
Perego 3
Pune 3
Savigliano 3
Tappahannock 3
Asunción 2
Cerveteri 2
Changsha 2
Hong Kong 2
Leicester 2
Loreto Aprutino 2
Moscow 2
Palagiano 2
Rome 2
Ameno 1
Amsterdam 1
Apo 1
Ascoli Piceno 1
Brdo 1
Campobasso 1
Canary Wharf 1
Castano Primo 1
Changchun 1
Colleferro 1
Copenhagen 1
Dallas 1
Dezhou 1
Edinburgh 1
Espoo 1
Frankfurt am Main 1
Grevenbroich 1
Guangzhou 1
Gunzenhausen 1
Handan 1
Harbin 1
Hunedoara 1
Istanbul 1
Jinan 1
Jinhua 1
La Paz 1
Lanciano 1
Langfang 1
Medford 1
Milan 1
Nanning 1
Nanyang 1
Ningbo 1
Pieve 1
Puyang Chengguanzhen 1
Redwood City 1
Seattle 1
Shaoxing 1
Sofia 1
Spoltore 1
Stanford 1
Stockholm 1
Suzhou 1
São Paulo 1
Totale 1.361
Nome #
Trastuzumab Emtansine (T-DM1) in Patients (pts) With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Metastatic Breast Cancer (MBC): results From a Multicenter Retrospective Analysis 108
"Triple positive" early breast cancer: An observational multicenter retrospective analysis of outcome 104
Neoadjuvant chemotherapy in triple-negative breast cancer: A multicentric retrospective observational study in real-life setting 100
Body Mass Index and Treatment Outcomes in Metastatic Breast Cancer Patients Treated With Eribulin 94
Impact of BMI on clinical outcome in advanced cancer patients treated with anti‑PD‑1 Immune checkpoint inhibitors: a preliminary analysis 93
A retrospective multicentric observational study of trastuzumab emtansine in HER2 positive metastatic breast cancer: a real-world experience 92
Long-term outcome of neoadjuvant endocrine therapy with aromatase inhibitors in elderly women with hormone receptor-positive breast cancer 90
Combination of peripheral neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio is predictive of pathological complete response after neoadjuvant chemotherapy in breast cancer patients 89
Anthropometric, clinical and molecular determinants of treatment outcomes in postmenopausal, hormone receptor positive metastatic breast cancer patients treated with fulvestrant: Results from a real word setting 88
Effect of Gender on the Outcome of Patients Receiving Immune Checkpoint Inhibitors for Advanced Cancer: A Systematic Review and Meta-Analysis of Phase III Randomized Clinical Trials 87
A Case of Stage I Vulvar Squamous Cell Carcinoma with Early Relapse and Rapid Disease Progression 87
Do cut-off values of lymph node ratio and presence of perineural invasion affect survival in breast cancer patients with pathologic N3a lymph node stage? Reply to Kadri Altundag 85
Body mass index modifies the relationship between γ-H2AX, a DNA damage biomarker, and pathological complete response in triple-negative breast cancer 83
Fasting glucose and body mass index as predictors of activity in breast cancer patients treated with everolimus-exemestane: The EverExt study 82
Fulvestrant 500 milligrams as endocrine therapy for endocrine sensitive advanced breast cancer patients in the real world: the Ful500 prospective observational trial. 79
Long-term outcome of breast cancer patients with pathologic N3a lymph node stage 79
Outcomes of HER2-positive early breast cancer patients in the pre-trastuzumab and trastuzumab eras: a real-world multicenter observational analysis. The RETROHER study 78
Weight loss and body mass index in advanced gastric cancer patients treated with second-line ramucirumab: a real-life multicentre study 78
Safety analysis, association with response and previous treatments of everolimus and exemestane in 181 metastatic breast cancer patients: A multicenter Italian experience 76
Predictive factors of response to neoadjuvant chemotherapy (NAT) in triple negative breast (TNBC) cancer patients: A restrospective multicenter observational study. 74
Triple positive early breast cancer in the pre- and post Trastuzumab eras: a subgroup analysis of a multicenter retrospective study. 73
Distinct HR expression patterns significantly affect the clinical behavior of metastatic HER2+ breast cancer and degree of benefit from novel anti-HER2 agents in the real world setting 70
Palbociclib plus endocrine therapy in HER2 negative, hormonal receptor-positive, advanced breast cancer: A real-world experience 69
Fulvestrant (FUL) 500 milligrams as endocrine therapy (ET) for hormone sensitive advanced breast cancer patients (pts). The Ful500 prospective observational trial 68
A multicenter REtrospective observational study of first-line treatment with PERtuzumab, trastuzumab and taxanes for advanced HER2 positive breast cancer patients. RePer Study 65
Prognostic relevance of DNA damage and repair biomarkers in elderly patients with hormone-receptor-positive breast cancer treated with neoadjuvant hormone therapy: evidence from the real-world setting 56
PANHER study: a 20-year treatment outcome analysis from a multicentre observational study of HER2-positive advanced breast cancer patients from the real-world setting 28
Prognostic Relevance of Neutrophil to Lymphocyte Ratio (NLR) in Luminal Breast Cancer: A Retrospective Analysis in the Neoadjuvant Setting 18
Totale 2.193
Categoria #
all - tutte 8.093
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 8.093


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/2020296 0 0 0 0 0 57 63 29 53 52 37 5
2020/2021139 20 1 31 2 7 30 3 4 5 5 3 28
2021/2022142 0 6 0 33 6 4 6 8 9 4 15 51
2022/2023561 38 75 38 77 48 100 22 55 69 7 21 11
2023/2024268 31 13 17 11 19 99 38 5 6 10 3 16
2024/2025237 30 67 63 27 10 40 0 0 0 0 0 0
Totale 2.193